Ionis Pharmaceuticals

News

MSD, Ionis trumpet lipid-lowering drug data

MSD's enlicitide scores in hypercholesterolaemia, as Ionis lines up broader use for recent approval Tryngolza in severe hypertriglyceridaemia.

News

Sanofi grabs Chinese rights to Arrowhead rare disease drug

Sanofi has paid $130 million upfront for Chinese rights to an Arrowhead Pharma drug for rare disease familial chylomicronaemia syndrome.

News

Lilly's appeal unlocks EU approval of Alzheimer's drug

Eli Lilly's appeal of a decision by the EMA's human medicines committee not to approve its Alzheimer's disease therapy Kisunla has paid off.

News

EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy

AstraZeneca and Ionis add an EU green light to earlier approvals in the US and UK for ATTR polyneuropathy drug Wainzua, a potential blockbuster.

News

FDA clears Ionis drug as first therapy for rare disease FCS

Ionis Pharma's Tryngolza (olezarsen) has become the first FDA-approved drug therapy for adults with rare disease familial chylomicronaemia syndrome.

News

AZ, Ionis get CHMP backing for ATTR polyneuropathy drug

AstraZeneca and Ionis are set fair for EU approval of Wainzua, their treatment for polyneuropathy associated with transthyretin-mediated amyloidosis (ATTR), after the EMA's human medicines

MSD, Ionis trumpet lipid-lowering drug data

Sanofi grabs Chinese rights to Arrowhead rare disease drug

Lilly's appeal unlocks EU approval of Alzheimer's drug

EU clears AZ, Ionis' Wainzua for ATTR polyneuropathy

FDA clears Ionis drug as first therapy for rare disease FCS

AZ, Ionis get CHMP backing for ATTR polyneuropathy drug

NHS staff 'feel unprepared for digital transformation'

How to meet your physicians where they are online

Ionis Pharmaceuticals

Editor's Picks